About Histogen

Histogen is a regenerative medicine company focused on developing patented, innovative technologies for aesthetic and therapeutic markets that replace and regenerate tissues in the body. The Company currently has three product candidates addressing underserved, multi-billion dollar global markets: a dermal filler, a treatment for hair loss, and a treatment for joint cartilage repair.

History

Histogen, Inc., a Delaware Corporation, was founded in 2007 to develop innovative products utilizing the proteins and growth factors produced by cells grown under simulated embryonic conditions. The Company is headquartered in San Diego, California.

Histogen founder Dr. Gail Naughton is a highly respected scientist with extensive experience in the field of tissue engineering and regenerative medicine. Dr. Naughton discovered the potential of proteins and growth factors produced by hypoxia-induced multipotent cells for therapeutic and biomedical applications, and developed Histogen’s unique technology process to create products based on these proteins. The technology is protected by patent families filed in the US and across key geographies.

Our Mission

To redefine regenerative medicine by developing high value therapeutic and aesthetic products that stimulate the body’s own stem cells to regenerate tissues, without the use of embryonic stem cells or animal components.

Management

Histogen’s Executive Management team has decades of experience in bringing cell-based regenerative products from concept to market. In addition, the Company’s Board of Directors and Scientific Advisors are leaders in the fields of regenerative medicine and global marketing and business operations. Histogen has brought on experienced consultants to advise the team in regulatory, quality and production areas.

Richard Pascoe

Richard W. Pascoe has been a director and served as Chairman and Chief Executive Officer of Histogen Incorporated since January of 2019.

Yizhuo Zhang

David H. Crean

David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions and 20 years of life sciences R&D and corporate development.